5.33
0.95%
0.05
アフターアワーズ:
5.36
0.03
+0.56%
前日終値:
$5.28
開ける:
$5.31
24時間の取引高:
694.70K
Relative Volume:
0.46
時価総額:
$237.22M
収益:
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.2968
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-6.98%
1か月 パフォーマンス:
+15.87%
6か月 パフォーマンス:
+55.85%
1年 パフォーマンス:
-52.03%
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.33 | 237.22M | 3.64M | -87.37M | -86.46M | -4.11 |
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-31 | 繰り返されました | BTIG Research | Buy |
2024-09-30 | 開始されました | Guggenheim | Buy |
2023-11-21 | 再開されました | BTIG Research | Buy |
2023-09-27 | 開始されました | B. Riley Securities | Buy |
2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
2022-09-07 | 再開されました | Alliance Global Partners | Buy |
2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
2022-03-09 | 開始されました | Truist | Buy |
2021-07-01 | 開始されました | Alliance Global Partners | Buy |
2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2018-07-13 | 開始されました | BTIG Research | Buy |
2018-05-02 | 開始されました | Seaport Global Securities | Buy |
2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-13 | 開始されました | Oppenheimer | Outperform |
2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
2015-09-09 | 開始されました | Raymond James | Strong Buy |
2015-05-12 | 繰り返されました | UBS | Buy |
2015-04-08 | 開始されました | H.C. Wainwright | Buy |
2015-01-23 | 繰り返されました | ROTH Capital | Buy |
2014-07-08 | 再開されました | Oppenheimer | Perform |
2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
Verastem Oncology announces debt refinancing with Oberland Capital - MSN
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace
Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India
Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Oncology Grants Stock Options to New Employee at $6.49 Exercise Price - StockTitan
Chugai Pharmaceutical Co., Ltd.Verastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Royal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - MarketBeat
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Verastem: Planning The PDUFA Run-Up (NASDAQ:VSTM) - Seeking Alpha
State Street Corp Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem: BLA Acceptance Puts Key Goals In Sight (NASDAQ:VSTM) - Seeking Alpha
Verastem soars on FDA priority review for avutometinib - The Pharma Letter
Verastem stock climbs on raised price target and FDA milestone for KRASm treatment - Investing.com Nigeria
Verastem stock remains volatile but promising data reinforces Buy rating by B.Riley - Investing.com Canada
BTIG Research Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Thera - GuruFocus.com
Verastem Shares Soar on FDA Priority Review of Cancer Treatment - Marketscreener.com
FDA sets priority review date for Verastem’s new ovarian cancer drug - The Business Journals
Regulatory Milestone Sends Verastem (VSTM) Shares Soaring - Stocks Telegraph
Stifel Financial Corp Buys 11,642 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application - Yahoo Finance
Verastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG Research - MarketBeat
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - BioSpace
Verastem Oncology's New Cancer Treatment Gets FDA Priority Review - Marketscreener.com
FDA accepts Verastem NDA for priority review, stock jumps 20% (update) - Seeking Alpha
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):